Results 121 to 130 of about 40,633 (287)

Cardiac amyloidosis [PDF]

open access: yesCanadian Journal of Cardiology, 2008
Ali K, Salah   +5 more
openaire   +2 more sources

Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta‐analysis

open access: yesESC Heart Failure, 2019
Aims The study aims to systematically assess the diagnostic performance of cardiac magnetic resonance (CMR) and nuclear scintigraphy (index tests) for the diagnosis and differentiation of subtypes of cardiac amyloidosis.
Jack Brownrigg   +3 more
doaj   +1 more source

Cardiovascular Magnetic Resonance in Cardiac Amyloidosis [PDF]

open access: yes, 2020
Background: Systemic amyloidoses are an underdiagnosed, but increasingly recognized group of progressive disorders characterised by the extracellular deposition of misfolded proteins in one or more organs.
Martinez de Azcona Naharro, Ana
core  

Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow   +4 more
wiley   +1 more source

Diagnostic and therapeutic challenges in rapidly progressing cardiac amyloidosis: a literature review based on case report

open access: yesInternational Journal of Emergency Medicine
Introduction Cardiac amyloidosis is a rarely reported and potentially fatal variant of the systemic disease. Its early diagnosis could potentially lead to significantly improved clinical outcomes.
Nahid Senobari   +7 more
doaj   +1 more source

Cardiac Amyloidosis Involving the Conduction System and the Aortocoronary Neuroreceptors [PDF]

open access: bronze, 1986
Alberto Volpi   +4 more
openalex   +1 more source

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata   +19 more
wiley   +1 more source

Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage

open access: yesEuropean Journal of Heart Failure, EarlyView.
Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy